(Methods, Tables) / Volume 1: |
Methods |
Introduction / 1: |
Experimental Section / 2: |
Origin and choice of samples / 2.1: |
Sample preparation / 2.2: |
Standard extraction procedures / 2.2.1: |
Standard liquid-liquid extraction (LLE) for plasma, urine or gastric contents (P, U, G) / 2.2.1.1: |
STA procedure (hydrolysis, extraction and microwave-assisted acetylation) for urine (U+UHYAC) / 2.2.1.2: |
Extraction of urine after cleavage of conjugates by glucuronidase and arylsulfatase (UGLUC) / 2.2.1.3: |
Extractive methylation procedure for urine or plasma (UME, PME) / 2.2.1.4: |
Solid-phase extraction for plasma or urine (PSPE, USPE) / 2.2.1.5: |
LLE of plasma for determination of drugs for brain death diagnosis / 2.2.1.6: |
Extraction of ethylene glycol and other glycols from plasma or urine followed by microwave-assisted pivalylation (PEGPIV or UEGPIV) / 2.2.1.7: |
Derivatization procedures / 2.2.2: |
Acetylation (AC) / 2.2.2.1: |
Methylation (ME) / 2.2.2.2: |
Ethylation (ET) / 2.2.2.3: |
tert.-Butyldimethylsilylation (TBDMS) / 2.2.2.4: |
Trimethylsilylation (TMS) / 2.2.2.5: |
Trimethylsilylation followed by trifluoroacetylation (TMSTFA) / 2.2.2.6: |
Trifluoroacetylation (TFA) / 2.2.2.7: |
Pentafluoropropionylation (PFP) / 2.2.2.8: |
Pentafluoropropylation (PFPOL) / 2.2.2.9: |
Heptafluorobutyrylation (HFB) / 2.2.2.10: |
Pivalylation (PIV) / 2.2.2.11: |
Heptafluorobutyrylprolylation (HFBP) / 2.2.2.12: |
GC-MS Apparatus / 2.3: |
Apparatus and operation conditions / 2.3.1: |
Quality assurance of the apparatus performance / 2.3.2: |
Determination of retention indices / 2.4: |
Systematic toxicological analysis (STA) of several classes of drugs and their metabolites by GC-MS / 2.5: |
Screening for 200 drugs in blood plasma after LLE / 2.5.1: |
Screening for most of the basic and neutral drugs in urine after acid hydrolysis, LLE and acetylation / 2.5.2: |
Systematic toxicological analysis procedures for the detection of acidic drugs and/or their metabolites / 2.5.3: |
General screening procedure for zwitterionic compounds after SPE and silylation / 2.5.4: |
Application of the electronic version of this handbook / 2.6: |
Quantitative determination / 2.7: |
Correlation between Structure and Fragmentation / 3: |
Principle of electron-ionization mass spectrometry (EI-MS) / 3.1: |
Correlation between fundamental structures or side chains and fragment ions / 3.2: |
Formation of Artifacts / 4: |
Artifacts formed by oxidation during extraction with diethyl ether / 4.1: |
N-Oxidation of tertiary amines / 4.1.1: |
S-Oxidation of phenothiazines / 4.1.2: |
Artifacts formed by thermolysis during GC (GC artifact) / 4.2: |
Decarboxylation of carboxylic acids / 4.2.1: |
Cope elimination of N-oxides (-(CH3)2NOH, -(C2H5)2NOH, -C6H14N2O2) / 4.2.2: |
Rearrangement of bis-deethyl flurazepam (-H2O) / 4.2.3: |
Elimination of various residues / 4.2.4: |
Methylation of carboxylic acids in methanol ((ME), ME in methanol) / 4.2.5: |
Formation of formaldehyde adducts using methanol as solvent (GC artifact in methanol) / 4.2.6: |
Artifacts formed by thermolysis during GC and during acid hydrolysis (GC artifact, HY artifact) / 4.3: |
Dehydration of alcohols (-H2O) / 4.3.1: |
Decarbamoylation of carbamates / 4.3.2: |
Cleavage of morazone to phenmetrazine / 4.3.3: |
Artifacts formed during acid hydrolysis / 4.4: |
Cleavage of the ether bridge in beta-blockers and alkanolamine antihistamines (HY) / 4.4.1: |
Cleavage of 1,4-benzodiazepines to aminobenzoyl derivatives (HY) / 4.4.2: |
Cleavage and rearrangement of N-demethyl metabolites of clobazam to benzimidazole derivatives (HY) / 4.4.3: |
Cleavage and rearrangement of bis-deethyl flurazepam (HY -H2O) / 4.4.4: |
Cleavage and rearrangement of tetrazepam / 4.4.5: |
(Methods, Tables) / Volume 1: |
Methods |
Introduction / 1: |
Experimental Section / 2: |
Origin and choice of samples / 2.1: |
Sample preparation / 2.2: |